Active Ingredient History
Yohimbine is a plant alkaloid with alpha-2-adrenergic blocking activity. Yohimbine has been used as a mydriatic and in the treatment of impotence. The exact mechanism for its use in impotence has not been fully elucidated. Yohimbine exerts antagonist actions at halpha(2A)-AR, h5-HT(1B), h5-HT(1D), and hD(2) sites, partial agonist actions at h5-HT(1A) sites. Yohimbine-mediated norepinephrine release at the level of the corporeal tissues may also be involved. In addition, beneficial effects may involve other neurotransmitters such as dopamine and serotonin and cholinergic receptors. Yohimbine has a mild anti-diuretic action, probably via stimulation of hypothalmic center and release of posterior pituitary hormone. Reportedly yohimbine exerts no significant influence on cardiac stimulation and other effects mediated by (beta)-adrenergic receptors. Its effect on blood pressure, if any, would be to lower it; however, no adequate studies are at hand to quantitate this effect in terms of Yohimbine dosage. Side effect of Yohimbine include anxiety, tremor, palpitations, diarrhea, and supine hypertension. NCATS
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Alcoholism (Phase 2)
Autonomic Nervous System Diseases (Phase 1)
Blood Flow Velocity (Phase 4)
Cigarette Smoking (Phase 1)
Cocaine-Related Disorders (Phase 2)
Depression (Phase 2)
Depressive Disorder, Major (Phase 2)
Diabetes Mellitus, Type 2 (Phase 2)
Dopamine beta-Hydroxylase (Phase 1)
Erectile Dysfunction (Phase 4)
Healthy Volunteers (Phase 2)
Heroin Dependence (Phase 1)
Homeostasis (Phase 4)
Hypertension (Early Phase 1)
Hypotension, Orthostatic (Phase 1)
Marijuana Abuse (Phase 1)
Ocular Physiological Phenomena (Phase 4)
Opioid-Related Disorders (Phase 2)
Orthostatic Intolerance (Phase 1)
Parkinson Disease (Early Phase 1)
Phobia, Social (Phase 3)
Psychological Distress (Phase 2)
Pure Autonomic Failure (Phase 1)
Stress Disorders, Post-Traumatic (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue